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Abstract
Liver fibrosis is a serious disease that affects around 350–400 million people worldwide.
The main approach for fibrosis staging is liver biopsy, which is an invasive procedure
that is not endured pretty well by patients. Currently, some serum-based biomarker
panels are available for diagnosis and staging of liver fibrosis. Recent high-throughput
proteomic studies are also very promising for identification of novel biomarkers for
diagnosis  and/or  treatment  of  liver  fibrosis.  We  hereby  review  the  application  of
proteomic profiling studies for identification of fibrosis biomarkers with their advan-
tages and drawbacks.
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1. Liver fibrosis
Liver fibrosis results from chronic damage to the liver and causes accumulation of excessive
matrix or scar. This scar tissue may inhibit blood flow due to the contraction of liver that results
progressive liver damage and cirrhosis (the most advanced stage of liver fibrosis) or even
hepatocellular carcinoma (HCC) [1]. Liver fibrosis is prominently observed in chronic liver
diseases  such as  viral  hepatitis,  alcoholic  steatohepatitis,  nonalcoholic  fatty liver  disease
(NAFLD), toxic liver injury, auto-immune diseases, and some genetic diseases [2]. From these
chronic liver diseases, chronic hepatitis B (CHB) and chronic hepatitis C are major global health
problems, and despite national vaccination programs, around 350–400 million people are
infected with hepatitis B virus (HBV) and 130–150 million people are infected with hepatitis C
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virus (HCV) worldwide [3, 4]. Chronic HBV (CHB) infection results in liver fibrosis that can
further develop into cirrhosis or HCC, both being the major causes of liver-related death [5].
The annual incidence of cirrhosis in patients infected with HBV has been evaluated at 1.3–2.4%
[6], and although the cumulative 5-year-old survival rate for patients with compensated cirrhosis
is 84% [7], in patients with decompensated cirrhosis, this survival rate decreases to 14–35% [7, 8].
Regeneration of liver is an extremely complex process, but recent studies in human and animal
models have indicated that liver fibrosis could be reversible in specific cases [9, 10]. It is hoped
that deeper understanding of the etiology of liver fibrosis will contribute to improved diag-
nostic tools and potential therapeutic approaches for liver fibrosis and cirrhosis. Even though
curing the underlying disease may reverse fibrosis progression, currently, the most effective
treatment that prolongs survival in advanced cirrhotic patients is liver transplantation [11].
However, this approach is limited because of the shortages of organs, the presence of concur-
rent disease affecting other tissues, and recurrence of the original disease in transplant
patients [12]. Despite the advancement in noninvasive tests, liver biopsy still remains as the
gold standard test for evaluation of liver disease severity [13–16]. However, it has several
disadvantages such as invasive character, sampling errors and limitations for effective
surveillance, and follow-up [17–19]. Upon antiviral treatment, HCV-infected patients may
clear HCV RNA from their bloodstream [5]. For the treatment of CHB, current therapies do
not accomplish complete eradication of HBV infection. HBV remains in infected hepatocytes
in the form of covalently closed circular DNA (cccDNA) even if the patient clears HBsAg, and
this cccDNA can possibly be reactivated with the right stimulus [20]. Hence, the therapeutic
strategy for CHB is to prevent liver fibrosis and the other complications of advanced liver
disease that can further develop cirrhosis and HCC. Therefore, recent studies focus on the
search of biomarkers for noninvasive diagnosis and staging of liver fibrosis and for discovery
of new therapeutic targets to prevent HBV-related liver fibrosis.
Proteomics, which studies the complex protein mixtures in a biological system, is a valuable
tool to investigate cellular pathways, protein–protein interactions, and identify target pro-
teins [21]. No requirement of a priori knowledge of protein identities present in a biological
system makes proteomic profiling an ideal tool for screening the most discerning set of
biomarkers [22].
In this review, we will focus on the advances in the proteomic research concerning liver fibrosis
and evaluate whether proteomic profiling studies are applicable in the search of protein
biomarkers and/or therapeutic targets for this condition with a focus on HBV and HCV
infection.
2. Pathogenesis and staging of liver fibrosis
Hepatic fibrosis develops as a result of wound healing response of the liver to chronic injury
in conjunction with the deposition of extracellular matrix (ECM) proteins [23]. Deposition of
ECM proteins forms a fibrous scar that alters hepatic architecture, and subsequent formation
of nodules of regenerating hepatocytes results in cirrhosis [24]. After an acute liver damage
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(e.g., HBV and HCV infection), parenchymal cells regenerate and substitute the necrotic and
apoptotic cells. This process is accompanied with an inflammatory response and minor
accumulation of ECM. Following persistent damage, eventually liver regeneration declines,
and hepatocytes are replaced with abundant ECM, including fibrillar collagen. Origin of liver
injury determines the distribution of this fibrous material. While in chronic hepatitis and
chronic cholestatic disorders, the localization of fibrotic tissue is around portal tracts, in
alcohol-induced liver diseases, its localization is in pericentral and perisinusoidal areas [25].
In the fibrotic liver, the main ECM-producing cells are hepatic stellate cells (HSCs) [26]. In the
healthy liver, HSCs are found in the space of Disse and act as the major repository sites of
vitamin A. Following sustained injury, HSCs activate or transdifferentiate into myofibroblast-
like cells that have contractile, proinflammatory, and fibrogenic characteristics [27, 28].
Activated HSCs, which migrate and accumulate at the wound repair locations, secrete bulk
amounts of ECM and mediate ECM degradation [29].
Some other hepatic cells, besides HSCs, may show fibrogenic properties. One of them is
myofibroblasts derived from small portal vessels which reproduce around biliary tracts in
cholestatis-induced liver fibrosis to induce collagen accumulation [30, 31]. The origin of the
liver injury may determine the relative significance of each cell type in liver fibrogenesis. For
instance, while HSCs exert the main fibrogenic activity in alcohol-induced liver fibrosis, portal
myofibroblasts may be the most crucial fibrogenic cell types in viral hepatitis or chronic
cholestatic disorders [1]. Thus, origin of liver injury may determine the molecular pathway
differentiation in the formation of each liver disease, affecting the final proteomic outcome.
During fibrosis development, a complex interaction occurs between different hepatic cell
types [32]. Most of the hepatoxic agents such as hepatitis viruses, alcohol metabolites, and bile
acids target hepatocytes [33]. Injured hepatocytes secrete reactive oxygen species (ROS) and
fibrogenic mediators, which triggers the activation of lymphocytes by inflammatory cells.
Apoptosis of these injured hepatocytes further induces the fibrogenic actions of liver myofi-
broblasts [34]. Inflammatory cells such as lymphocytes and polymorphonuclear cells stimulate
HSCs for collagen synthesis [35]. Activated HSCs also release inflammatory chemocines,
secrete cell adhesion molecules, and mediate activation of lymphocytes [36]. Thus, a fierce cycle
in which inflammatory and fibrogenic cells induce each other likely appears [37]. Kupffer cells,
which are the local macrophages of liver, also greatly participate in liver inflammation by
secreting ROS and cytokines [38, 39]. In conclusion, fibrogenesis is directly activated by
alterations in the ECM composition and this altered ECM can serve as a repository for MMPs,
growth factors, and inflammatory cytokines [1, 40].
Fibrosis progression is generally evaluated by two different accepted scoring systems: Ishak
(modified Knodell score) and METAVIR scores. While in METAVIR, only interface hepatitis
and lobular necrosis are used to determine the grade of activity, in Ishak, portal infiltrate and
confluent necrosis are included with the two previous parameters [41]. Generally, fibrosis
begins to develop as expansion of portal tracts occurring with interface hepatitis. As fibrosis
advances, portal-portal linkage develops in conjunction with septa formation. At the end,
fibrous tissue completely surrounds hepatocyte nodules. While complete cirrhosis develops
generally in several years in some circumstances such as in the case of viral hepatitis, following
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liver transplantation cirrhosis may develop much more rapidly. Parenchymal fibrosis can also
be observed in the presence of lobular inflammation, especially in areas of bridging necrosis
[42]. This may be the cause of portal-central septa formation, which has been considered as
more crucial process in the development of cirrhosis than portal-portal linkages [43]. In the
terminology of liver fibrosis, septa indicate expansion of portal tract edges without formation
of bridges or actual connection between portal areas or portal area and central vein. On the
other hand, the term bridge is used to assess actual fibrous connection between two portal
areas or portal area and central vein [44]. It is important to consider these mentioned staging
systems in a descriptive sense that a patient with stage 2 fibrosis cannot be assumed to have
sustained twice as much liver damage as one with stage 1 fibrosis, nor half as much as one
with stage 4 fibrosis because numerical stages are not evenly distributed along the progression
of fibrosis, and also transition from one stage to the next one is not linear. Nonetheless,
pathologists’ interobserver agreement in fibrosis staging among one stage is approximately
90% [45, 46].
3. Biomarkers of liver fibrosis
An optimal biomarker of liver fibrosis would not get affected by functional distress in liver or
kidneys and only be specific to liver, also be easily observed with simple, inexpensive, and
noninvasive assays [13]. Liver enzymes that are routinely measured in serum such as alanine
transaminase (ALT) and aspartate transaminase (AST) are not suitable biomarkers of liver
fibrosis as they have poor correlation with liver fibrosis. Studies demonstrated that 20% of the
biopsy-proven cirrhotic patients’ ALT levels are in normal range [47]. Unfortunately, canonical
markers of liver synthetic dysfunction [e.g., albumin, platelet count (PLT), prothrombin time
(PT)] are shown to be unsuccessful in the detection of early fibrotic stages [48]. Currently, novel
serum proteins have been observed with altered expression in progressing liver fibrosis such
as apolipoprotein A1 (ApoA1), serum transferrin, and alpha 2 macroglobulin [49–51]. Bio-
marker panels that incorporate combination of these individual markers are also applicable
for improved accuracy of fibrotic stage assessment [46]. The most currently used biomarker
panels are AST to platelet ratio index [52], FibroTest that includes apolipoprotein A1 (ApoA1),
haptoglobin (HPT), gamma-glutamyl transpeptidase (γGT), γ-globin, total bilirubin, and
alanine aminotransferase as biomarkers [53], and FibroIndex that combines PLT, AST, and
γGT [54]. These noninvasive biomarker panels have shown to achieve good negative predictive
scores in patients with low fibrosis stages and good positive predictive scores in those with
advanced stages. However, intermediate fibrotic stages are not successfully interpreted by
these combined biomarkers [53]. Unfortunately, this setback limits the use of current available
biomarker panels for routine clinical assessments of liver fibrosis [55].
4. Current proteomic profiling methodologies
Proteomics, which is a swiftly developing area, is currently preferred in discovery of novel
disease biomarkers due to its potential to surpass the drawbacks of traditional screening
Advances in Treatment of Hepatitis C and B358
methods. The first step of the proteomic biomarker screening research is to separate and profile
whole proteome of the biological fluid (e.g., serum, whole blood, saliva) or tissue of interest.
Then, protein profile of the diseased sample is compared with a relevant control to identify
the differentially expressed proteins related to that disease. Several different techniques based
on in-gel separation and/or mass spectrometry are currently used for protein separation.
Mass spectrometry (MS) is the common technique in proteomic profiling methodologies. The
basic concept of mass spectrometry is to evaluate the mass-to-charge (m/z) ratio for determi-
nation of the exact mass of the protein. The components of a mass spectrometry are an ion
source, a mass analyzer, and a mass detector. Ionization of proteins is done either with matrix-
assisted laser desorption/ionization (MALDI) or electrospray ionization (ESI). Following
ionization, proteins pass through one or two mass analyzers that measure their m/z ratio (MS
or versus tandem MS/MS). Time-of-flight (TOF) that measures the time spent by the protein
through the vacuum tube in an electric field can be coupled with one or two quadrupoles (Q-
TOF or Q-Q-TOF) with oscillating electric field that enables molecules with specific m/z ratios
to travel without collision [56, 57].
4.1. Two-dimensional gel electrophoresis (2D-PAGE)
The 2D-PAGE technique separates protein according to two independent parameters, isoelec-
tric point and molecular weight, and therefore provides the best resolution possible in protein
separation currently [58, 59]. Following staining and digitalization with specific softwares,
protein quantitation is performed by evaluation of spot intensities. 2D-PAGE also enables
detection of posttranslational modifications, such as phosphorylation, or presence of different
protein isoforms due to the emerging shifts in protein mass or isoelectric point [46]. In addition,
two-dimensional difference gel electrophoresis (2D-DIGE) presents various advances includ-
ing reproducibility, detection sensitivity, and credibility of analysis [60–62]. In 2D-DIGE,
different samples are labeled with charge- and mass-matched fluorescent cyanine dyes, Cy3
and Cy5. The internal standard prepared by mixing equal amounts of all samples is labeled
by Cy2. The Cy3 and Cy5 labeled samples and Cy2 labeled internal standard are then mixed
and co-separated on the same 2-DE gel, providing accurate spot detection and intra-gel
matching with reduced experimental variations. Running internal standard within all gels also
improves gel-to-gel spot matching and enables for statistically strong comparisons between
protein samples [63]. At the end, protein spots cut from 2D gels were identified by mass
spectrometry [64].
4.2. Liquid chromatography coupled mass spectrometry (LC-MS)
Gel-based techniques such as 2D-PAGE are not very successful and reliable for profiling of
small (>10 kDa) or hydrophobic proteins; besides, the evaluation of large numbers of samples
is time-consuming and expensive. LC-MS, which couples a prefractionation stage with
different types of mass spectrometry, is a relatively new gel-free proteomic methodology for
proteomic profiling. One of the highly used MS methods is MALDI-TOF. In this technique,
first, protein mixtures are fractionated by their physicochemical characteristics such as
hydrophobicity or isoelectric point by liquid chromatography. Then, bound proteins are
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vaporized and ionized by a laser. Finally, peptide mass is computed from the time spend to
reach the detector (“time-of-flight”). Another frequently applied method is LC-MS/MS which
efficiently profiles large numbers of samples with the analysis of extremely small volume
samples (i.e., <75 µl) by evaluating proteins with masses ranging from 2 to 200 kDa with
tremendous efficiency and reasonable reproducibility [65]. In addition, SELDI-TOF MS, which
couples a prefractination stage with MALDI-TOF, is currently used for proteomic profiling
studies. In SELDI, protein mixtures that selectively bind to an array with a specified charac-
teristic are analyzed. This methodology requires very low amount of crude sample, such as
serum or needle biopsy samples, and it is very efficient in analysis of low molecular weight
proteins. Considering the minimal labor required for SELDI application, this technique is very
useful for high-throughput screening. However, higher cost of SELDI still limits its large
clinical scale usage [66–68].
5. Proteomic profiling studies in search of biomarkers for liver fibrosis
Proteomic studies on liver fibrosis mainly focus on cirrhosis and HCC, which are the very end
and morbid stage of liver fibrosis. One of the earlier studies has compared tumor tissue and
surrounding nontumor tissue from eight HCC patients and has showed overexpression of
14-3-3γ protein in HCC [69]. Another study has investigated the proteomic differences between
tumor and adjacent nontumor tissue samples of 12 HBV-associated HCC patients and has
found out upregulation of members of the heat shock protein 70 and 90 families and down-
regulation of metabolism-associated mitochondrial and peroxisomal proteins in HCC [70]. A
recent study has analyzed sera of 40 HCC patients and 47 healthy controls and has discovered
leucine-rich α2-glycoprotein (LRG) and haptoglobin (HPT) between HCV- and HBV-related
HCC [71]. Molleken and Sitek (72) also have analyzed cirrhotic septa and liver parenchyma of
seven cirrhotic patients and discovered an increase in cell structure-associated proteins, which
are actin, prolyl 4-hydroxylase, tropomyosin, calponin, transgelin, and human microfibril-
associated protein 4 (MFAP-4). However, all these studies investigate the alterations occurring
at the very end stage of fibrosis and did not give information about the proteomic changes
during fibrosis progression.
To identify therapeutic targets and their involved pathways in fibrosis, the proteomic
changes between different fibrotic stages should be investigated. There are several studies
that focus on proteomic changes between different fibrotic stages. One of these studies has
investigated serum protein profiles of HCV-infected patients and has showed that Mac-2-
binding protein, α-2-macroglobin, and hemopexin were increased in cirrhosis, and α-1-anti-
trypsin, LRG, and fetuin-A (also named as alpha-2-HS-glycoprotein) were decreased in
cirrhosis [73]. A recent research, which has enrolled sera of 16 healthy controls and 45 HCV
patients with different fibrotic stages graded due to METAVIR, has found out that α-2-mac-
roglobin (A2M) was increased, while vitamin D-binding protein (VDBP) and apolipoprotein
A1 (ApoA1) were decreased in late fibrosis [51]. One of the studies examining serum sam-
ples of seven healthy controls and 27 HBV-infected patients with different stages of fibrosis
has shown that fibrinogen, collagen, A2M, hemopexin, α-1-antitrypsin, transthyretin, and
Advances in Treatment of Hepatitis C and B360
thiredoxin peroxidase were upregulated, while HPT, serotransferrin, CD5 antigen-like pro-
tein, clusterin, ApoA1, and LRG were downregulated along with fibrogenesis [74]. A recent
study has analyzed sera of 19 CHB, six HBV-related cirrhotic patients, and five healthy con-
trols and observed increased plasma myeloperoxidase levels in cirrhotic patients and de-
creased transthyretin, ceruloplasmin, and α-1-antitrypsin levels in both CHB- and HBV-
related cirrhosis patients and downregulation of ApoA1 in HBV-related cirrhosis [75]. These
studies about liver fibrosis have revealed the proteomic changes of serum samples through-
out fibrogenesis. There are few studies that investigated proteomic changes in HCV-associ-
ated fibrogenesis. Diamond et al. demonstrated the effect of oxidative stress proteins to
fibrosis progression in biopsy samples of HCV-infected patients [76]. The same group re-
cently analyzed proteomic mechanisms of HCV-mediated liver fibrosis in posttransplant re-
cipients by LC-MS (liquid chromatography coupled mass spectrometry) and demonstrated
once again the important role of enhanced oxidative stress in the rapid fibrosis progression
observed in HCV-infected liver transplant patients [77]. Ferrin et al. studied liver biopsies of
HCV-infected alcoholic patients with cirrhosis for altered proteins in the progression of
HCC and observed deregulation of ceruloplasmin (CP), paraoxanase (PON1), complement
component 4a (CD4a), and fibrinogen-α (FGA) expression [78]. Another study investigated
the differences in the protein profiles between liver samples from HBV-infected transgenic
mouse and nontransgenic mouse and demonstrated increased aldehyde dehydrogenase 2
(ALDH2), protein disulfide isomerase precursor (PRDX1), actin, 78 kDa glucose-regulated
protein (GRP78), tumor rejection antigen (GRP94), keratin 18 (KRT18), and decreased gluta-
mate dehydrogenease 1 (GLUD1) and high mobility group 1 (HMGB1) protein levels [79].
An extensive list of potential biomarkers emerging from these studies is listed in Table 1.
Currently, studies also focused on understanding whether proteomic alterations may predict
the treatment response in chronic hepatitis C. Hence, the effect of pegylated interferon
(PegIFN) plus ribavirin (RBV) therapy, which is the common HCV treatment, may be under-
stood better. When the serum samples from patients with chronic hepatitis C were subjected
to metabolomics analysis to investigate the pretreatment and posttreatment characteristics of
their metabolites by using capillary electrophoresis and liquid chromatography coupled mass
spectrometry, tryptophan has been found to be associated with response to PegIFN/RBV
therapy [82]. Moreover, identification of factors that predict virological response to antiviral
therapy may improve treatment response through patient-specific treatment strategy. Recent
studies revealed significant variances in proteome profiles throughout longitudinal serum
samples in virological responders, in patients with mild fibrosis, and in those with mild
necroinflammation [83]. In the current phase 2 studies (PROVE1, PROVE2, and PROVE3) of
the direct-acting antiviral drug telaprevir, serum samples from responders and nonresponders
to HCV treatment were analyzed by proteomic profiling and 15 differentially expressed
proteins, with seven of them belonging to focal adhesion proteins or other macromolecular
assemblies that constitute structural links between integrins and the actin cytoskeleton, were
observed [84]. The ultimate goal of performing pretreatment serum proteome profiling prior
to treatment is to predict sustained virological response (SVR) and nonresponse (NR) to
antiviral drugs in chronic HCV infection and design suitable treatments for each patient.
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Protein Proteomic Analysis Sample Disease Positive or
Nagative Markera
Reference
5’-3’ exoribonuclease 1 LC-MS Liver biopsy HCV + [77]
78 kDa glucose regulated protein,
GRP78
2D-DIGE Mouse liver tissue HBV + [79]
A-1-antitrypsin 2D-PAGE Serum HCV - [73]
2D-DIGE Serum HBV + [74]
Actin 2D-PAGE Liver tissue HCV + [72]
2D-DIGE Mouse liver tissue HBV + [79]
Aldehyde dehydrogenase 2 2D-DIGE Mouse liver tissue HBV + [79]
Apolipoprotein A1 2D-PAGE Serum CHB - [75]
2D-DIGE Serum HBV - [74]
2D-DIGE Serum HCV - [51]
Aryl sulfotransferase 1A3 LC-MS Liver biopsy HCV + [77]
Bone martr stromal cell antigen 2 LC-MS Liver biopsy HCV + [77]
Calponin LC-MS Liver biopsy HCV + [80]
2D-PAGE liver tissue HCV + [72]
Carboxymethylenebutenolisade
homologue
LC-MS Liver biopsy HCV - [77]
CD44 antigen LC-MS Liver biopsy HCV + [77]
CD5 antigen like protein 2D-DIGE Serum HBV - [74]
Ceruloplasmin 2D-DIGE Serum HCV + [78]
Clusterin 2D-DIGE Serum HBV - [74]
Collagen 2D-DIGE Serum HBV + [74]
LC-MS Liver biopsy HCV + [80]
Complement component 4a 2D-DIGE Serum HCV + [78]
Cystathione beta synthase LC-MS Liver biopsy HCV - [77]
Cysteine and glycine rich protein 2LC-MS Liver biopsy HCV + [80]
Cytochrome b-245 beta LC-MS Liver biopsy HCV + [77]
Cytochrome c LC-MS Liver biopsy HCV + [76]
Fetuin A 2D-PAGE Serum HCV - [73]
Fibrinogen 2D-DIGE Serum HCV + [78]
2D-DIGE Serum HBV + [74]
Fibulin-5 LC-MS Liver biopsy HCV + [80]
FK506 binding protein 14 LC-MS Liver biopsy HCV - [77]
Gelsolin 2D-PAGE Serum HBV - [81]
Glutamate dehydrogenase 1 2D-DIGE Mouse liver tissue HBV - [79]
Gluthatione-S-transferases LC-MS Liver biopsy HCV - [77]
Haptoglobin 2D-PAGE Serum HCV - [73]
2D-DIGE Serum HBV - [74]
Hemopexin 2D-PAGE Serum HCV + [73]
2D-DIGE Serum HBV + [74]
High mobility group 1 2D-DIGE Mouse liver tissue HBV - [79]
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Protein Proteomic Analysis Sample Disease Positive or
Nagative Markera
Reference
Human leukocyte antigen class 2
antigen DR beta 1
LC-MS Liver biopsy HCV + [77]
Human leukocyte antigen class I
antigen C
LC-MS Liver biopsy HCV + [77]
Keratin 18 2D-DIGE Mouse liver tissue HBV + [79]
Leucine-rich α-2-glycoprotein 2D-PAGE Serum HCV - [73]
2D-DIGE Serum HBV - [74]
Leukotriene LC-MS Liver biopsy HCV + [77]
Lumican LC-MS Liver biopsy HCV + [80]
Mac-2-binding protein 2D-PAGE Serum HCV + [73]
Macroglobin 2D-PAGE Serum HCV + [73]
2D-DIGE Serum HBV + [74]
2D-DIGE serum HCV + [51]
Microfibril-associated
glycoprotein 4
LC-MS Liver biopsy HCV + [80]
2D-PAGE liver tissue HCV + [72]
Paraoxanase 1 2D-DIGE Serum HCV + [78]
Peroxiredoxin 1 2D-DIGE Mouse liver tissue HBV + [79]
Peroxiredoxin 2 2D-DIGE Serum HBV - [74]
Peroxiredoxin 5 LC-MS Liver biopsy HCV +/- [76]
Plasma myeloperoxidase 2D-PAGE Serum CHB + [75]
Prealbumin 2D-DIGE Serum HBV + [74]
Pre-angiotensionogen LC-MS Liver biopsy HCV +/- [77]
Prolyl 4-hydroxylase 2D-PAGE liver tissue HCV + [72]
Protein disulfide isomerase
precursor
2D-DIGE Mouse liver tissue HBV + [79]
Proteosome beta subunit type 4 LC-MS Liver biopsy HCV + [77]
Retinal dehydrogenase LC-MS Liver biopsy HCV +/- [76]
Serotransferrin 2D-DIGE Serum HBV - [74]
Serum amyloid A1 LC-MS Liver biopsy HCV +/- [77]
Superoxide dismutase 1 LC-MS Liver biopsy HCV - [77]
Thioredoxin reductase 1 LC-MS Liver biopsy HCV + [77]
Transgelin LC-MS Liver biopsy HCV + [80]
2D-PAGE liver tissue HCV + [72]
Tropomyosin 2D-PAGE liver tissue HCV + [72]
Tumor rejection antigen, GRP94 2D-DIGE Mouse liver tissue HBV + [79]
Vitamin D binding protein 2D-DIGE serum HCV - [51]
a Proteins up- (+) or downregulated (S) in liver fibrosis, as detected in proteomic studies.
b When multiple comparisons have been performed between individual fibrosis stages certain proteins might have
been reported as positive and negative markers.
Table 1. Candidate biomarkers of liver fibrosis identified from proteomic studies.
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6. Limitations of proteomics
Proteomics have been shown as a promising tool in the evaluation of the molecular insights
of liver fibrosis and in complementing previously known fibrosis biomarkers. Proteomic
research is prone to unexpected and sometimes unpredictable biases [85]. Especially in analysis
with multiple testing, extensive care should be given to assure that alterations observed are
biologically significant and associated with the target disease [86]. Moreover, the unstable
nature of biological samples makes them prone to degradation and alteration during sample
processing [87]. Low-abundant proteins such as some stress expressed proteins and transcrip-
tion factors are quite hard to be detected by proteomic screening.
Over 90% of the total serum protein concentration is constituted by some abundant proteins
such as albumin and immunoglobins. Therefore, these abundant proteins may prevent
detection of low-abundant proteins [88]. Depletion of serum from high-abundant proteins may
increase the resolution and detection of low-abundance proteins [89]. However, while
depleting serum from albumin, some potentially important proteins may bind to albumin and
be lost for the upcoming analysis [90].
For the tissue samples, the diagnostic quality of biopsied tissue is limited for the evaluation of
liver fibrosis. Presentation of only a very small part of the liver (approximately 1/50,000) by
needle biopsy causes high sampling variability [91, 92]. Especially since fibrotic tissue is not
distributed homogeneously inside the liver, sampling errors form 10% of false-negative
diagnoses [91]. Moreover, interobserver agreement is not very high for particularly intermedi-
ate fibrosis stages. By considering these facts altogether, proteomic studies of liver fibrosis carry
a robust characteristic.
7. Future directions and concluding remarks
Future studies in search of biomarkers for liver fibrosis should involve an adequate reference
standard. Moreover, it is fairly possible that each chronic liver disease (CLD) could have its
etiology-specific biomarkers, and further research should cover the identification of optimal
biomarker sets for each cause of CLD (such as HBV, HCV, NASH, alcohol abuse). Serum
proteomic studies might be combined with imaging techniques such as MALDI imaging to
improve the performance of noninvasive techniques [93].
In summary, proteomic studies offer a great insight into differentially expressed proteins in
plasma and hepatic tissue of patients with liver fibrosis. The results of this proteomic knowl-
edge present researchers a better understanding about the pathobiology of liver fibrosis and
lead to the discovery of the best set of biomarkers for the noninvasive assessment of the clinical
stage of patients.
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